GLP-1s have transformed obesity treatment, demonstrating “unprecedented efficacy” in weight reduction. Yet many patients discontinue these medications because of adverse effects or cost, and weight regain is common. 

A recent meta-analysis found that approximately half of GLP-1 users discontinued treatment within the first year. Most regained approximately 60% of the weight they lost within a year of stopping treatment. Another meta-analysis, involving more than 9300 patients published in The BMJ, found that people returned to their pretreatment weight an average of 1.7 years after discontinuation.

“Obesity is like any other chronic medical condition,” Marsha Novick, MD, medical director of Weight Management & Wellness Online, told Medscape Medical News. “For instance, we can anticipate that discontinuing asthma medication would result in worsening of asthma symptoms. The same occurs when stopping medication that treats obesity.”

Novick, a spokesperson for The Obesity Society, noted that weight regain is broadly similar across GLP-1 drugs. 

“No particular GLP-1 has been shown to offer more protection than other GLP-1s against rebound weight gain once the medication is stopped,” she said.

Powerful Biological Mechanisms

Weight regain after GLP-1 discontinuation reflects several intersecting processes, particularly the return of appetite. 

Sam West, PhD, a postdoctoral researcher at the Nuffield Department of Primary Care Health Sciences, University of Oxford, UK, and lead author of The BMJ meta-analysis, explained that the appetite-suppressing effects of GLP-1 medications diminish after cessation. 

“Once you stop taking the medication, those feelings of hunger quickly return. It’s not as simple as controlling what you eat. You’re fighting against powerful biological mechanisms,” he told Medscape Medical News.

Franchell Hamilton, MD, a bariatric surgeon and founder of the NeuroSwitch Weight Loss Institute, also emphasized the return of hunger and cravings. 

“GLP-1 drugs chemically suppress appetite and reduce ‘food noise.’ When they’re discontinued without addressing underlying neurological habit loops or metabolic adaptations, hunger cues rebound sharply, often accompanied by heightened cravings, which lead to weight gain,” she said.

Behavioral and psychological factors, including stress-related eating, increased portion sizes, reduced confidence, and weight stigma, also contribute to weight regain. The modern-day obesogenic environment, characterized by ultra-processed foods, sedentary behavior, and socioeconomic barriers, can compound these challenges. 

The Plateau Effect 

Although weight regain is common, not everyone who discontinues GLP-1s returns to their pretreatment weight. 

A meta-analysis published in eClinicalMedicine found that weight regain was most rapid during the first several months after discontinuation. Beyond a year, weight regain was estimated to plateau at approximately 75% of the initial weight loss.

Researchers have proposed several explanations for this plateau effect, including the possibility that healthier eating habits adopted during treatment persist after discontinuation. GLP-1s may also exert beneficial long-term physiologic effects. 

Novick emphasized there is great variance in the amount of weight regain.

“We can anticipate that most people regain about half to two thirds of the weight they lost within a year of discontinuing the medication. This means that a person may still end up weighing less than they did before starting GLP-1 treatment,” she said. 

Pre-discontinuation Strategies

“The best advice I can give is for people to continue taking their [GLP-1] medications,” West said.

For patients who cannot do so, switching to another GLP-1 medication may be an option. A 2020 consensus statement noted that patients may respond differently to individual agents, making switching potentially viable when intolerable side effects, cost, formulary changes, or insurance mandates interfere with treatment. 

West also suggested that switching from an injectable to an oral formulation of the same medication may be helpful. 

However, he noted that robust, evidence-based guidance on discontinuation strategies is lacking, given the relative newness of GLP-1s.

Nevertheless, a 2026 editorial published in American Family Physician outlined three potential approaches:

• Dose de-escalation: Gradually reducing the dose at controlled intervals to limit weight regain and abrupt increases in appetite. Preliminary research suggests that tapering semaglutide alongside lifestyle interventions may help sustain weight loss for at least 20 weeks after discontinuation.
• Interval dosing: Progressively extending the time between injections, taking advantage of the long half-life of these medications. A small chart review found that patients who had achieved weight and/or metabolic goals maintained their weight loss with every-other-week dosing over an average of 32 weeks.
• Adding an oral obesity medication: Introducing a medication such as phentermine or phentermine-topiramate during dose reduction to supplement appetite suppression.

The authors emphasized that these discontinuation strategies must be “paired with renewed commitment to lifestyle modifications.”

Structured Lifestyle Support 

Novick concurred with the need to incorporate such modifications into prediscontinuation strategies, pointing to research suggesting that adding regular aerobic exercise to obesity pharmacotherapy may help minimize weight regain after discontinuation. 

A recently published randomized study also examined the potential benefits of structured support. Adults who had lost weight while taking GLP-1 medications were assigned after discontinuation to usual care, a digital wellness application, or medically tailored meals delivered to their homes.

Compared with usual care, both intervention groups experienced significantly less weight gain over 4 months. The differences were -7.16% with the digital intervention and -7.17% with medically tailored meals. 

“We found that participants who received either medically tailored meals or behavioral support were better able to maintain their weight loss than participants receiving usual care, up to 4 months after stopping the medication,” lead author Kelseanna Hollis-Hansen, PhD, MPH, a research assistant professor at Tufts University’s Food is Medicine Institute, Boston, Massachusetts, told Medscape Medical News.

“While larger and longer studies are needed, our findings suggest that structured lifestyle support may help people navigate this challenging transition and maintain some of the health benefits they achieved while taking the medication,” she said. 

Hollis-Hansen, who is also a consultant and program advisor at the Center for Nutrition and Health Impact, emphasized the importance of continued follow-up. 

“Ongoing monitoring can help determine whether patients may benefit from dose re-titration, switching to another anti-obesity medication, or intensifying behavioral treatment,” she said. 

A multidisciplinary approach involving nutrition, mental health, exercise, and individualized medical management can provide additional support.

Beyond Standard Dietary Advice

According to Hamilton, author of Transformation Is a Mind-Set: The Journey to Changing Your Input and Your World, it’s essential to “move beyond standard dietary advice, which often falls short when it focuses solely on calorie counting or macronutrient tracking rather than the underlying drivers of eating behaviors.” 

She regards “active behavioral wiring as the critical missing link in post-GLP-1 maintenance.” 

During GLP-1 treatment, appetite is suppressed passively, which may reduce opportunities to practice managing cravings, Hamilton explained. Once medication is stopped, patients may struggle with the return of hunger and food noise.

She recommends behavioral techniques that disrupt automatic habits and help patients recognize and interrupt their responses to stress, fatigue, and environmental eating cues while they are still taking the medication.

Hamilton uses this approach through her proprietary NeuroSwitch method, which she offers to patients undergoing bariatric surgery or taking weight-loss medications. 

Cognitive behavioral therapy (CBT) has an established role in long-term weight management. Mindfulness- and acceptance-based approaches may complement CBT by helping patients respond differently to cravings and eating-related triggers.

The Role of Bariatric Surgery 

For some patients who regain weight after discontinuing GLP-1 therapy, metabolic and bariatric surgery may be an option.

Novick suggested that surgery may be appropriate for selected patients with a BMI above 35 kg/m². 

“It often helps people lose about one out of every 3-4 pounds of their body weight and many keep much of it off for 10 years or longer,” she said. 

Hamilton also emphasized the potential role of surgery for patients with severe obesity or metabolic disease who have difficulty sustaining pharmacotherapy or experience a weight-loss plateau, noting that “bariatric surgery remains one of the most durable interventions by permanently altering metabolic signaling, gut peptides, and hunger physiology.”

Talking to Patients About GLP-1s

West stressed the importance of discussing management plans at the outset of GLP-1 therapy.

“Have deep conversations about long-term planning before patients begin taking these drugs,” he said. “Patients should be aware that they might be taking them for life and the risk of weight regain [upon discontinuation] needs to be made clear at the start.” 

Hollis-Hansen encouraged clinicians to explain that “increased difficulty maintaining weight after stopping a GLP-1 medication isn’t a sign of failure.” 

Patients should understand that weight regulation is “complex, biologically driven, and strongly influenced by an environment in which highly processed, calorie-dense foods are abundant, and healthier options are often less accessible.”

Hollis-Hansen is a paid program advisor for the Special Supplemental Nutrition Program for Women, Infants, and Children Community Innovation and Outreach program on behalf of the Center for Nutrition & Health Impact. After the study was completed and submitted for publication, she received grant funding from Noom to conduct a larger, longer follow‐up study. Hamilton created the NeuroSwitch Method and founded Crave & Switch, a mobile application focused on habit rewiring and craving management. Novick has served on the Novo Nordisk advisory board. West has reported no relevant financial relationships. 

Batya Swift Yasgur, MA, LSW is a freelance writer with a counseling practice in Teaneck, NJ. She is a regular contributor to numerous medical publications, including Medscape and WebMD, and is the author of several consumer-oriented health books as well as Behind the Burqa: Our Lives in Afghanistan and How We Escaped to Freedom (the memoir of two brave Afghan sisters who told her their story).